{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,21]],"date-time":"2023-05-21T04:28:15Z","timestamp":1684643295071},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T00:00:00Z","timestamp":1539820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1038\/s41409-018-0362-7","type":"journal-article","created":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T15:09:47Z","timestamp":1539875387000},"page":"746-748","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease"],"prefix":"10.1038","volume":"54","author":[{"given":"Panayotis","family":"Kaloyannidis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eshrak Al","family":"Shaibani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Apostolidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solaf","family":"Kanfar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid Al","family":"Anezi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hani Al","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,18]]},"reference":[{"key":"362_CR1","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/bmt.2013.107","volume":"49","author":"T Ruutu","year":"2014","unstructured":"Ruutu T, Gratwohl A, de Witte T, Afanasyev B, Apperley J, Bacigalupo A, et al. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. Bone Marrow Transplant. 2014;49:168\u201373.","journal-title":"Bone Marrow Transplant"},{"key":"362_CR2","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.bbmt.2012.04.005","volume":"18","author":"PJ Martin","year":"2012","unstructured":"Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012;18:1150\u201363.","journal-title":"Biol Blood Marrow Transplant"},{"key":"362_CR3","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1038\/leu.2015.212","volume":"29","author":"R Zeiser","year":"2015","unstructured":"Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015;29:2062\u20138.","journal-title":"Leukemia"},{"key":"362_CR4","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.exphem.2016.05.005","volume":"44","author":"AS Al-Homsi","year":"2016","unstructured":"Al-Homsi AS, Feng Y, Duffner U, Al Malki MM, Goodyke A, Cole K, et al. Bortezomib for the prevention and treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Exp Hematol. 2016;44:771\u20137.","journal-title":"Exp Hematol"},{"key":"362_CR5","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","volume":"130","author":"D Miklos","year":"2017","unstructured":"Miklos D, Cutler CS, Arora M, Waller EK, Jagasia M, Pusic I, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017;130:2243\u201350.","journal-title":"Blood"},{"key":"362_CR6","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1056\/NEJMra1703472","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med. 2017;377:2565\u201379.","journal-title":"N Engl J Med"},{"key":"362_CR7","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.beha.2006.10.002","volume":"20","author":"F Dazzi","year":"2007","unstructured":"Dazzi F, Fozza C. Disease relapse after haematopoietic stem cell transplantation: risk factors and treatment. Best Pract Res Haematol. 2007;20:311\u201327.","journal-title":"Best Pract Res Haematol"},{"key":"362_CR8","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.bbmt.2017.12.797","volume":"24","author":"MA Schroeder","year":"2018","unstructured":"Schroeder MA, Choi J, Staser K, Di Persio JF. The role of janus kinase signaling in graft-versus-host-disease and graft versus leukemia. Biol Blood Marrow Transplant. 2018;24:1125\u201334.","journal-title":"Biol Blood Marrow Transplant"},{"key":"362_CR9","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/s41409-017-0081-5","volume":"53","author":"HJ Khoury","year":"2018","unstructured":"Khoury HJ, Langston AA, Kota VK, Wilkinson JA, Pusic I, Jillella A, et al. Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease. Bone Marrow Transplant. 2018;53:826\u201331.","journal-title":"Bone Marrow Transplant"},{"key":"362_CR10","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1016\/j.bbmt.2014.06.040","volume":"20","author":"AF Herrera","year":"2014","unstructured":"Herrera AF, Kim HT, Bindra B, Jones KT, Alyea EP 3rd, Armand P, et al. A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2014;20:1737\u201343.","journal-title":"Biol Blood Marrow Transplant"},{"key":"362_CR11","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.canlet.2017.06.016","volume":"403","author":"MB Oliveira De","year":"2017","unstructured":"De Oliveira MB, Fook-Alves VL, Eugenio AIP, Fernando RC, Sanson LFG, de Carvalho MF, et al. Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK\/STAT pathway inhibition in myeloma patients. Cancer Lett. 2017;403:206\u201310.","journal-title":"Cancer Lett"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0362-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0362-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0362-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:13:18Z","timestamp":1684617198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-018-0362-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,18]]},"references-count":11,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["362"],"URL":"https:\/\/doi.org\/10.1038\/s41409-018-0362-7","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,18]]},"assertion":[{"value":"16 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}